Frazier Life Sciences Management, L.P. Phathom Pharmaceuticals, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $2.36 Billion
- Q3 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 12,466,489 shares of PHAT stock, worth $183 Million. This represents 6.03% of its overall portfolio holdings.
Number of Shares
12,466,489
Previous 12,466,489
-0.0%
Holding current value
$183 Million
Previous $120 Million
19.29%
% of portfolio
6.03%
Previous 6.31%
Shares
4 transactions
Others Institutions Holding PHAT
# of Institutions
151Shares Held
65.3MCall Options Held
1.15MPut Options Held
170K-
Medicxi Ventures Management (Jersey) LTD7.46MShares$110 Million12.93% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.08MShares$74.6 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.86MShares$56.8 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$51.4 Million50.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.22MShares$47.2 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $575M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...